KROS Q3 2023 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$414M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8,000

Gross Profit

-$543,000-6787.5% margin

Operating Income

-$43M-541000.0% margin

Net Income

-$39M-493000.0% margin

EPS (Diluted)

$-1.33

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$35M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$326M

Total Liabilities

$30M

Stockholders' Equity

$296M

Cash & Equivalents

$288M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8,000	$0	—
Gross Profit	-$543,000	$0	—
Operating Income	-$43M	-$28M	-54.7%
Net Income	-$39M	-$24M	-67.8%